全文获取类型
收费全文 | 1677篇 |
免费 | 177篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 24篇 |
妇产科学 | 29篇 |
基础医学 | 133篇 |
口腔科学 | 53篇 |
临床医学 | 110篇 |
内科学 | 441篇 |
皮肤病学 | 19篇 |
神经病学 | 93篇 |
特种医学 | 39篇 |
外科学 | 186篇 |
综合类 | 3篇 |
预防医学 | 85篇 |
眼科学 | 28篇 |
药学 | 105篇 |
中国医学 | 13篇 |
肿瘤学 | 491篇 |
出版年
2023年 | 6篇 |
2022年 | 10篇 |
2021年 | 44篇 |
2020年 | 32篇 |
2019年 | 35篇 |
2018年 | 52篇 |
2017年 | 39篇 |
2016年 | 36篇 |
2015年 | 69篇 |
2014年 | 72篇 |
2013年 | 99篇 |
2012年 | 123篇 |
2011年 | 145篇 |
2010年 | 67篇 |
2009年 | 54篇 |
2008年 | 103篇 |
2007年 | 109篇 |
2006年 | 102篇 |
2005年 | 70篇 |
2004年 | 79篇 |
2003年 | 102篇 |
2002年 | 70篇 |
2001年 | 54篇 |
2000年 | 42篇 |
1999年 | 48篇 |
1998年 | 12篇 |
1997年 | 7篇 |
1996年 | 8篇 |
1995年 | 8篇 |
1993年 | 8篇 |
1992年 | 13篇 |
1991年 | 12篇 |
1990年 | 11篇 |
1989年 | 11篇 |
1988年 | 8篇 |
1987年 | 5篇 |
1986年 | 12篇 |
1985年 | 8篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1979年 | 3篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1974年 | 3篇 |
1973年 | 7篇 |
1972年 | 3篇 |
1971年 | 5篇 |
1969年 | 5篇 |
排序方式: 共有1857条查询结果,搜索用时 15 毫秒
61.
Camille Brasselet Miguel Cortes Morichetti Emmanuel Messas Claire Carrion Alvine Bissery Patrick Bruneval Jean-Thomas Vilquin Antoine Lafont Albert A Hagège Philippe Menasché Michel Desnos 《European heart journal》2005,26(15):1551-1556
AIMS: This study was designed to assess the functional effects of a transvenous coronary sinus technique of skeletal myoblast delivery in infarcted myocardium. METHODS AND RESULTS: An anterior myocardial infarction was created percutaneously in 14 sheep. Simultaneously, a muscle biopsy was harvested and expanded. Two weeks later, sheep were instrumented percutaneously with a dedicated catheter incorporating an extendable needle for puncture of the venous wall and, under endovascular ultrasound guidance, a microcatheter was advanced through the needle into the target scar for cell delivery. Following the baseline echocardiographic assessment of left ventricular (LV) function, sheep were randomly allocated to receive four-staged in-scar injections of either autologous cells (n=7) or culture medium (n=7). Two months later, LV function was reassessed blindly and hearts were explanted for subsequent histological and immunohistochemical analysis. There were no acute procedural complications. Baseline LV ejection fraction (EF) was significantly lower in transplanted sheep than in controls [38% (35-48) vs. 51% (38-55), respectively, P=0.03; median (range)]. Two months later, LVEF was significantly higher in the transplanted group than in controls [50% (47-56) vs. 39% (36-47), respectively, P=0.002]. Clusters of myoblasts were identified by histology and immunohistochemistry in three of the seven transplanted sheep. CONCLUSION: These data suggest the functional efficacy of the transvenous coronary sinus technique as a less invasive means of cell delivery to infarcted myocardium. 相似文献
62.
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia 总被引:12,自引:3,他引:12
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kantarjian H Gandhi V Cortes J Verstovsek S Du M Garcia-Manero G Giles F Faderl S O'Brien S Jeha S Davis J Shaked Z Craig A Keating M Plunkett W Freireich EJ 《Blood》2003,102(7):2379-2386
In a phase 2 study, 62 patients with relapsed and refractory acute myeloid leukemia (AML; n = 31), myelodysplastic syndrome (MDS; n = 8), chronic myeloid leukemia in blastic phase (CMLBP; n = 11), and acute lymphocytic leukemia (ALL; n = 12) received 40 mg/m2 clofarabine intravenously over 1 hour daily for 5 days, every 3 to 6 weeks. Twenty patients (32%) achieved complete response (CR), 1 had a partial response (PR), and 9 (15%) achieved CR but without platelet recovery (CRp), for an overall response rate of 48%. In AML, responses were noted in 2 (18%) of 11 patients in first salvage with short first CR (= 12 months), in 7 (87%) of 8 patients with longer first CR, and in 8 (67%) of 12 patients in second or subsequent salvage. Responses were observed in 4 of 8 patients with high-risk MDS (50%), in 7 (64%) of 11 with CML-BP, and in 2 (17%) of 12 with ALL. Severe reversible liver dysfunction was noted in 15% to 25%. After the first clofarabine infusion, responders accumulated more clofarabine triphosphate in blasts compared with nonresponders (median 18 vs 10 microM; P =.03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance. 相似文献
63.
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia 总被引:10,自引:6,他引:10
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kantarjian HM O'Brien S Cortes JE Giralt SA Rios MB Shan J Giles FJ Thomas DA Faderl S De Lima M Garcia-Manero G Champlin R Arlinghaus R Talpaz M 《Blood》2002,100(5):1590-1595
Twenty-eight adults with chronic myelogenous leukemia (CML) that had relapsed after allogeneic stem cell transplantation (SCT) received imatinib mesylate (400-1000 mg/d). Disease was in chronic phase in 5 patients, accelerated in 15, and blastic in 8 (7 medullary, 1 extramedullary); median time from transplantation to relapse was 9 months (range, 1-137 months). Thirteen patients had undergone salvage donor lymphocyte infusion (DLI) (median time from DLI to imatinib mesylate therapy, 4 months [range, 2-39 months]). The overall response rate was 79% (22 of 28 patients); the complete hematologic response (CHR) rate was 74% (17 of 23 patients), and the cytogenetic response rate was 58% (15 of 26 patients; complete response in 9 [35%] patients). CHR rates were 100% for chronic phase, 83% for accelerated phase, and 43% for blastic phase. The patient with extramedullary blastic disease achieved complete response. Cytogenetic response rates were 63% (12 of 19 patients) for chronic or accelerated phases (complete cytogenetic response in 8) and 43% for blastic phase (3 of 7 patients). At median follow-up of 15 months, 19 patients were alive, 9 with no evidence of disease. The 1-year estimated survival rate was 74%. Five patients had recurrence of grade 3 (3 patients) or grades 1 to 2 (2 patients) graft-versus-host disease (GVHD). Severe granulocytopenia developed in 43% of patients and thrombocytopenia in 27%; both conditions reversed with dose adjustments of imatinib mesylate. We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD. 相似文献
64.
Cortesão E Vidan J Pereira J Gonçalves P Ribeiro ML Tamagnini G 《Haematologica》2004,89(10):1261-1263
We report the case of a 40-year female who manifested late onset, pyridoxine-refractory X-linked sideroblastic anemia, heterozygous for the first described frameshift ALAS2 mutation, CD506-507 (-C). On presentation she had macrocytic anemia with severe iron overload. 相似文献
65.
Orsolic N Giles FJ Gourdeau H Golemovic M Beran M Cortes J Freireich EJ Kantarjian H Verstovsek S 《British journal of haematology》2004,124(6):727-738
The in vitro and in vivo activity of a deoxycytidine analogue, troxacitabine, alone or in combination with imatinib mesylate (IM), was evaluated against human chronic myeloid leukaemia (CML) cell lines both sensitive (KBM5 and KBM7) and resistant (KBM5-R and KBM7-R) to IM. These cell lines differ in their sensitivity to IM but all showed similar sensitivity to treatment with troxacitabine (IC50 = 0.5-1 micromol/l). Combined treatment with troxacitabine and IM revealed additive or synergistic effects. Greater apoptotic response was seen with combined treatment than with either agent alone in KBM7-R cells. In clonogenic assays, troxacitabine showed activity against mononuclear cells from CML patients (IC50 = 0.01 micromol/l) with either IM-sensitive or resistant disease. In vivo efficacy studies were carried out in severe combined immunodeficient mice bearing KBM5 or KBM5-R cells. Troxacitabine was administered i.p. daily for 5 d starting on day 20, at doses of 5, 10, 20, or 25 mg/kg. IM was administered i.p. twice a day for 10 d at a dose of 50 mg/kg starting on day 25. In this setting of late stage disease, troxacitabine led to a significant increase in life span, while IM did not. When IM was combined with troxacitabine at 10 and 25 mg/kg in the KBM5 xenograft model, a further increase in life span was observed and some mice achieved long-term survival. These data indicate that the combination of troxacitabine and IM has significant preclinical activity in advanced CML and that clinical evaluation of this combination is warranted. 相似文献
66.
Cornelia Zeidler Ulrike A.H. Grote Anna Nickel Beate Brand G?ran Carlsson Emília Cortes?o Carlo Dufour Caroline Duhem Gundula Notheis Helen A. Papadaki Hannah Tamary Geir E. Tj?nnfjord Fabio Tucci Jan Van Droogenbroeck Christiane Vermylen Jaroslava Voglova Blanca Xicoy Karl Welte 《Haematologica》2014,99(8):1395-1402
Long-term granulocyte-colony stimulating factor treatment has been shown to be safe and effective in severe chronic neutropenia patients. However, data on its use during pregnancy are limited. To address this issue, we analyzed all pregnancies reported to the European branch of the Severe Chronic Neutropenia International Registry since 1994. A total of 38 pregnancies in 21 women with chronic neutropenia (16 pregnancies in 10 women with congenital, 10 in 6 women with cyclic, 12 in 5 women with idiopathic neutropenia) were reported. Granulocyte-colony stimulating factor was administered throughout pregnancy in 16 women and for at least one trimester in a further 5 women. No major differences were seen between treated and untreated women with respect to pregnancy outcome, newborn complications and infections. In addition, we evaluated the genetic transmission of known or suspected genetic defects in 16 mothers having 22 newborns as well as in 8 men fathering 15 children. As a proof of inheritance, neutropenia was passed on to the newborn in 58% from female and in 62% from male patients with ELANE mutations, but also to some newborns from parents with unknown gene mutation. Based on our results, granulocyte-colony stimulating factor therapy has been shown to be safe for mothers throughout pregnancies and for newborns without any signs of teratogenicity. With an increasing number of adult patients, genetic counseling prior to conception and supportive care of mothers during pregnancy are crucial. The acceptance of having affected children may reflect the high quality of life obtained due to this treatment. 相似文献
67.
Michele Baccarani Brian J. Druker Susan Branford Dong-Wook Kim Fabrizio Pane Lidia Mongay Manisha Mone Christine-Elke Ortmann Hagop M. Kantarjian Jerald P. Radich Timothy P. Hughes Jorge E. Cortes François Guilhot 《International journal of hematology》2014,99(5):616-624
The TOPS trial evaluated high- (800 mg/day; n = 319) versus standard-dose (400 mg/day; n = 157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Patients had a minimum follow-up of 42 months or discontinued early. Major molecular response (MMR) rates were similar between arms at (51.6 vs 50.2 % for 400 and 800 mg/day, respectively; P = 0.77) and by (75.8 vs 79.0 %; P = 0.4807) 42 months. There were no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (OS) between arms. The estimated rates of PFS on treatment and OS at 42 months were significantly higher in patients with MMR at 6, 12, and 18 months compared with those without MMR. Adverse events were more frequent with high-dose imatinib. Patients with ≤1 treatment interruption (vs >1) and those able to maintain imatinib ≥600 mg/day (vs <600 mg/day) in the first year of treatment had faster and higher response rates, but no improvement in EFS or PFS. Adherence to prescribed dose without interruption may be more important than initiation of therapy with higher doses of imatinib. Achievement of MMR correlated with long-term clinical outcomes. 相似文献
68.
Yasmin Abaza Hagop Kantarjian Yasmin Alwash Gautam Borthakur Richard Champlin Tapan Kadia Guillermo Garcia-Manero Naval Daver Farhad Ravandi Srdan Verstovsek Jan Burger Zeev Estrov Maro Ohanian Miranda Lim Naveen Pemmaraju Elias Jabbour Jorge Cortes 《American journal of hematology》2020,95(11):1288-1295
Treatment of advanced-phase chronic myeloid leukemia (CML) remains unsatisfactory. Single-agent tyrosine kinase inhibitors have modest and short-lived activity in this setting. We conducted a phase I/II study to determine safety and efficacy of the combination of dasatinib and decitabine in patients with advanced CML. Two different dose schedules were investigated with a starting decitabine dose of either 10 mg/m2 or 20 mg/m2 daily for 10 days plus dasatinib 100 mg daily. The target dose level was decitabine 10 mg/m2 or 20 mg/m2 daily for 10 days plus dasatinib 140 mg daily. Thirty patients were enrolled, including seven with accelerated-phase CML, 19 with blast-phase CML, and four with Philadelphia-chromosome positive acute myeloid leukemia. No dose-limiting toxicity was observed at the starting dose level with either schedule. Grade ≥3 treatment emergent hematological adverse events were reported in 28 patients. Thirteen patients (48%) achieved a major hematologic response and six (22%) achieved a minor hematologic response, with 44% of these patients achieving a major cytogenetic response and 33% achieving a major molecular response. Median overall survival (OS) was 13.8 months, with significantly higher OS among patients who achieved a hematologic response compared to non-responders (not reached vs 4.65 months; P < .001). Decitabine plus dasatinib is a safe and active regimen in advanced CML. Further studies using this combination are warranted. 相似文献
69.
Maro Ohanian Philippe Telouk Steven Kornblau Francis Albarede Peter Ruvolo Rebecca S. S. Tidwell Adriana Plesa Rashmi Kanagal-Shamanna Eva-Laure Matera Jorge Cortes Arch Carson Charles Dumontet 《American journal of hematology》2020,95(4):422-434
Despite abundant epidemiological data linking metals to leukemia and other cancers, baseline values of toxic and essential metals in patients with leukemia and the clinical impact of these metals remain unknown. Thus, we sought to quantify metal values in untreated patients with acute myeloid leukemia (AML) and controls and determine the impact of metal values on AML patients' survival. Serum samples from patients with untreated AML and controls at Hospices Civils de Lyon were analyzed and compared for trace metals and copper isotopic abundance ratios with inductively coupled plasma mass spectrometry. Survival analysis was performed as a function of metal values, and a multi-metal score was developed for patients with AML. Serum samples were collected from 67 patients with untreated AML and 94 controls. Most patients had intermediate-risk cytogenetics (63.1%) without FLT3 internal tandem duplication mutations (75.6%) or NPM1 mutations (68.1%). Most metal values differed significantly between AML and control groups. Patients with lower magnesium and higher cadmium values had the worst survival rates, with only 36% surviving at 6 months (P = .001). The adverse prognostic effect of this combination was maintained on multivariate analysis. Based on this, we developed a novel metal score, which accounts for multiple relative abnormalities in the values of five toxic and five essential metals. Patients with a higher metal score had significantly worse survival, which was maintained on multivariate analysis (P = .03). This baseline metal scoring system was also prognostic when we applied it to a separate population of front-line AML patients. 相似文献
70.
Maro Ohanian Hagop M. Kantarjian Mahran Shoukier Sara Dellasala Arine Musaelyan Graciela M. Nogueras Gonzalez Elias Jabbour Lynne Abruzzo Srdan Verstovsek Gautam Borthakur Farhad Ravandi Guillermo Garcia-Manero Gevorg Tamamyan Richard Champlin Sherry Pierce Alessandra Ferrajoli Tapan Kadia Jorge E. Cortes 《American journal of hematology》2020,95(10):1127-1134
We aimed to describe the impact of time to response on the outcomes of 75 patients with accelerated-phase chronic myeloid leukemia (CML-AP) at diagnosis. Patients had at least 1 feature of AP: blasts ≥15% (n = 2), basophils ≥20% (n = 19), platelets <100 × 109/L (n = 7), cytogenetic clonal evolution (n = 34), or more than one factor (n = 13). Thirty-three patients received imatinib; 42 received a second-generation tyrosine kinase inhibitor (2GTKI) (19 dasatinib and 23 nilotinib). We used chi-square and Kaplan-Meier analyses to determine the impact of various degrees of molecular and cytogenetic response at early time points (3 and 6 months) on rates of overall cytogenetic and molecular response, overall survival (OS), event-free survival (EFS), transformation-free survival (TFS), and failure-free survival (FFS). After a median follow-up of 96 months (range: 18-224 months), the overall rate of complete cytogenetic response was 79%, of major molecular response, 71%, and of molecular reponse (MR)4.5, 59%. Patients who achieved a major cytogenetic response (MCyR) (n = 49) at 3 months had significantly better 3-year OS (94% vs 75%; P = .002), TFS (98% vs 73%; P < .001), EFS (93% vs 42%; P < .001), and FFS (83% vs 25%; P < .001) rates than patients who did not have MCyR at 3 months. Most (67%) who eventually achieved sustained MR4.5 had achieved MCyR at 3 months. In de novo CML-AP, early response at 3 and 6 months is a strong determinant of long-term outcome. 相似文献